Relmada Therapeutics (RLMD) Panoramica del titolo
Relmada Therapeutics, Inc. opera come società di biotecnologie in fase clinica negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
+ 1 più rischio
RLMD Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Relmada Therapeutics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$7.42 |
| Massimo di 52 settimane | US$8.00 |
| Minimo di 52 settimane | US$0.38 |
| Beta | 0.43 |
| Variazione di 1 mese | 3.20% |
| Variazione a 3 mesi | 99.46% |
| Variazione di 1 anno | 1,694.87% |
| Variazione a 3 anni | 138.59% |
| Variazione a 5 anni | -80.06% |
| Variazione dall'IPO | -87.63% |
Notizie e aggiornamenti recenti
Recent updates
Nuova narrazione • Mar 20
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?
Nuova narrazione • Mar 05
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsive behavior disorders such as Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Mar 21
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged. RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin. Read the full article on Seeking AlphaArticolo di analisi • Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jan 14
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Summary Relmada Therapeutics is developing REL-1017, a therapy for CNS diseases that targets hyperactive GluN2D channels in NMDA receptors. Phase 2 trial showed a rapid and sustained antidepressant effect in patients who did not respond to standard antidepressants. Phase 3 trial missed its primary endpoint, but post-hoc analysis showed a robust difference between REL-1017 and placebo when excluding certain clinical sites. Read the full article on Seeking AlphaArticolo di analisi • Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Oct 14
Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Truist and Guggenheim have downgraded Relmada Therapeutics (NASDAQ:RLMD) to hold and neutral, respecitvely, following the failure of phase 3 depression REL-1017. Truist lowered its price target to $10 from $90 (~54% upside based on Thursday's close) while Guggenheim doesn't have a target. Truist analyst Joon Lee wrote that based on conversations with key opinion leaders, REL-1017 would have faced headwinds on approval due to a REMS requirement and DEA scheduling. Guggenheim is removing its sales estimated for REL-1017. Analyst Yatin Suneja wrote that Relmada could still salvage the candidate by either adding substantially more participants to the RELIANCE 1 trial or persuade regulators to exclude patients from the handful of sites where a high placebo effect was observed. However, Suneja conceded the second option is less likely. Seeking Alpha's Quant Rating views Relmada (RLMD) as a hold with high marks for momentum and growth.Seeking Alpha • Sep 14
Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Summary We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid, effective, safe, and durable. Looking at the robust mechanism of action and phase 2 clinical data, we believe the clinical data to hold in phase 3. The key catalyst is REL-1017's phase 3 data that is expected in Q4 22 which we believe will move the stock price substantially and we are planning to start establishing a small option-sized position of the ticker. Background Relmada Therapeutics (NASDAQ:RLMD) is a US-based, pre-commercial stage biotech developing therapies for depressive disorders. The company is trading at a 700M enterprise value and holds 200M cash, which is a highly robust cash runway for a clinical-stage company. Accordingly, we initiate RLMD with a strong BUY rating. RLMD IR deck (RLMD IR deck) The unique mechanism of action of REL-1017 is key for best-in-class efficacy and safety REL-1017 is a novel first-in-class compound formulation of oral dextromethadone currently being studied to target depressive disease. We highlight that REL-1017 is the only compound that uniquely targets NMDA receptors to treat depression. The drug's key compositions are dextromethadone, the purified "d" enantiomer of methadone. We note that this is important for the drug's exceptional safety, a racemic mixture of "d" and "l" methadone is currently used to treat patients with opioid addiction problems; however, the "d" form lacks substantial opioid receptor activity and instead works as an NMDA receptor antagonist and channel blocker, similar to ketamine. Phase 2 efficacy and safety data points were effective and clean, we are optimistic about the success of the drug in phase 3 We highlight the key takeaways from phase 2 trials i) effective and durable anti-depressant effects on all tested scales, ii) rapid onset of action, with detected efficacy by day 4, iii) robust safety without opioid-related adverse events, psychotomimetic adverse events, and metabolic side-effects were shown, and iv) convenience - the drug is orally administered with a QD tablet formulation. RLMD IR deck (RLMD IR deck) Key findings are: Subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement of their depression compared to subjects in the placebo group on all efficacy measures, including: the MADRS; the Clinical Global Impression – Severity (CGI-S) scale; the Clinical Global Impression – Improvement (CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ). The improvement on the MADRS appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after treatment discontinuation, with p-values <0.03 and large effect sizes (a measure of quantifying the difference between two groups), ranging from 0.7 to 1.0. Similar findings emerged from the CGI-S and CGI-I scales. Source: company IR deck We believe REL-1017's remarkable potency combined with the drug's rapid and sustained effects make it the best-in-class agent currently being developed. We highlight that REL-1017 demonstrated impressive separation from placebo on the MADRS endpoint on Day 14. In comparison to SOCs, the ~9.4–10.4 reduction compared to placebo is more than double the reduction seen with approved anti-depressants. This level of efficacy was achieved in a more challenging, treatment-refractory patient population, which is highly promising moving forward in terms of commercial potential. Keeping the difference in study design in mind, if we compare REL-1017 to fellow NMDA receptor antagonists, Spravato, Spravato only demonstrated a 4.0 reduction in MADRS score over placebo at day 28 in its pivotal TRANSFORM-2 trial. RLMD IR deck (RLMD IR deck) RLMD IR deck (RLMD IR deck) as shown above (REL-1017 phase 2 study safety data (Company IR) No serious treatment-emergent adverse events were shown. In terms of safety, the global safety profile seems superior to Spravato as there were no reported dissociative/psychomimetic effects. Furthermore, there were no signs of opioid withdrawal upon treatment discontinuation. The most common adverse events included mild to moderate headache, nausea, and sedation, which were evenly distributed across the treatment arms, which does not concern us, and we believe the drug has a robust profile with a favorable risk/benefit as an MDD therapeutic candidate. Furthermore, we believe REL-1017's oral formulation to be more convenient for patients than Spravato's intranasal administration as it is less discrete. We believe the phase 3 trial design is robust and the endpoints are achievable for the drug based on their robust phase 2 performanceSeeking Alpha • Aug 09
Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Relmada Therapeutics (NASDAQ:RLMD) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to its drug, REL-1017, as a monotherapy to treat major depressive disorder. (RLMD) rose 3.3% premarket. For a fast track drug, the company must show some advantage over current therapy, such as superior effectiveness, effect on serious outcomes or improved effect on serious outcomes, and avoiding serious side effects of an available therapy. A drug that receives Fast Track designation is eligible for Accelerated Approval and Priority Review.Articolo di analisi • Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 28
4 Clinical Catalysts On Tap For Relmada In 2022
RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLMD longs. The timing of readouts allows for an interesting potential trade, avoiding exposure to an earlier study which I feel has more downside than upside potential.Articolo di analisi • Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Jun 28
Our First Look At Relmada Therapeutics
Relmada Therapeutics, Inc.’s (RLMD) sole clinical asset, oral antidepressant therapy esmethadone, is undergoing two pivotal trials for the treatment of MDD. Phase 2 study data demonstrate a rapid onset of action that no other currently approved oral therapy can boast. Despite esmethadone’s promise, Axsome Therapeutics (AXSM) has a similar oral candidate (AXS-05) with a novel MOA and August 22nd, 2021 PDUFA date, suggesting an ~18-month head start. A full investment analysis is presented in the paragraphs below.Articolo di analisi • Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
If you want to know who really controls Relmada Therapeutics, Inc. ( NASDAQ:RLMD ), then you'll have to look at the...Rendimenti per gli azionisti
| RLMD | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | -0.1% | -13.2% | 1.1% |
| 1Y | 1,694.9% | 39.4% | 26.7% |
Ritorno vs Industria: RLMD ha superato il US Pharmaceuticals che ha restituito 39.4 % nell'ultimo anno.
Rendimento vs Mercato: RLMD ha superato il mercato US che ha restituito 26.7 % nell'ultimo anno.
Volatilità dei prezzi
| RLMD volatility | |
|---|---|
| RLMD Average Weekly Movement | 19.7% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di RLMD è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 20% ) di RLMD è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2004 | 17 | Sergio Traversa | www.relmada.com |
Relmada Therapeutics, Inc. opera come società di biotecnologie in fase clinica negli Stati Uniti. L'azienda si concentra sullo sviluppo di NDV-01, una formulazione intravescicale a rilascio controllato di gemcitabina e docetaxel, in fase di sperimentazione clinica di Fase 2 per i pazienti affetti da forme aggressive di tumore alla vescica non muscolo-invasivo, e di Sepranolone, un neurosteroide epimero dell'allopregnanolone, pronto per la Fase 2b per il potenziale trattamento della sindrome di Prader-Willi, della sindrome di Tourette, dell'eccessivo tremore e di altre patologie correlate all'eccessiva attività GABAergica. L'azienda ha un accordo con Asarina Pharma AB e Trigone.
Relmada Therapeutics, Inc. Riepilogo dei fondamenti
| RLMD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$785.61m |
| Utili (TTM) | -US$58.88m |
| Ricavi(TTM) | n/a |
0.0x
Rapporto P/S-13.2x
Rapporto P/ERLMD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| RLMD Conto economico (TTM) | |
|---|---|
| Ricavi | US$0 |
| Costo del fatturato | US$0 |
| Profitto lordo | US$0 |
| Altre spese | US$58.88m |
| Utili | -US$58.88m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -0.56 |
| Margine lordo | 0.00% |
| Margine di profitto netto | 0.00% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato RLMD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/14 18:01 |
| Prezzo dell'azione a fine giornata | 2026/05/14 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Relmada Therapeutics, Inc. è coperta da 10 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Farzin Haque | Jefferies LLC |
| Andrew Berens | Leerink Partners LLC |